

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Port delivery platform with ranibizumab for treating wet age-related macular degeneration [ID3983]

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<u>Company</u> <ul style="list-style-type: none"> Roche (port delivery platform with ranibizumab) 	<u>General</u> <ul style="list-style-type: none"> All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health - Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation NHS Wales Joint Commissioning Committee Scottish Medicines Consortium Wales Council for the Blind Welsh Government
<u>Patient/carer groups</u> <ul style="list-style-type: none"> Eyecare Trust Fight for Sight Macular Society National Federation of the Blind of the UK Network of Sikh Organisations Retina UK Royal National Institute of Blind People SeeAbility Sense South Asian Health Foundation Specialised Healthcare Alliance Thomas Pocklington Trust 	
<u>Professional groups</u> <ul style="list-style-type: none"> Association of Optometrists British and Eire Association of Vitreoretinal Surgeons British and Irish Orthoptic Society British Geriatrics Society British Ophthalmic Anaesthesia Society College of Optometrists Optical Confederation Royal College of General Practitioners Royal College of Nursing Royal College of Ophthalmologists Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association 	<u>Comparator companies</u> <ul style="list-style-type: none"> ADVANZ Pharma (aflibercept) Bayer (aflibercept) Celltrion Healthcare (aflibercept) Genus Pharmaceuticals (ranibizumab) MDBiologics (aflibercept) Novartis (brolucizumab, ranibizumab) Orion Pharma (ranibizumab) Outlook Therapeutics (bevacizumab gamma) Roche (faricimab) Samsung Bioepis (ranibizumab) Sandoz (aflibercept) Teva UK (ranibizumab)
	<u>Relevant research groups</u>

Provisional stakeholder list for the evaluation of port delivery platform with ranibizumab for treating wet age-related macular degeneration [ID3983].

Issue date: December 2025

© National Institute for Health and Care Excellence 2025. All rights reserved.

Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • UK Ophthalmic Pharmacy Group <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England 	<ul style="list-style-type: none"> • Cochrane Eyes and Vision Group • Cochrane UK • Eye Hope • Genomics England • Institute of Ophthalmology, University College London • MRC Clinical Trials Unit • National Eye Research Centre Charity • National Institute for Health Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.

that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.